Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM...
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE Labège, France, June 05,...
View ArticleAntabio Receives QIDP Designation from the U.S. FDA for the Development of...
Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681 Labège, France, 21 June 2019. Antabio SAS, a private biopharmaceutical company...
View ArticleAntabio applauds the new mechanism for reimbursement of antibiotics set up by...
Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US On August 2, 2019, the US government announced several significant changes to hospital antibiotic...
View ArticleAntabio Awarded $4.4 Million from CARB-X for the Further Development of its...
The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies. Download the full press release hereTélécharger le...
View ArticleAntabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation...
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem...
View ArticleAntabio Awarded EUR 0.9 million funding from the Occitanie Region to support...
Télécharger le communiqué en version française The post Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel...
View ArticleLaunch of ARPEGE, a French multidisciplinary consortium to fight antibiotic...
Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million...
View ArticleAntabio Announces First Subjects Dosed in Phase 1 Clinical Trial of...
MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii....
View ArticleAntabio is seeking a Regulatory Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleANTABIO Raises €25 million in Series B Financing
Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion...
View Article
More Pages to Explore .....